ANIX

$2.89

Market ClosedAs of Mar 17, 8:00 PM UTC

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.89
Potential Upside
5%
Whystock Fair Value$3.03
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T ce...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$96.47M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.52
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-68.06%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
11.49

Recent News

MarketBeat
Mar 13, 2026

Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress

Anixa Biosciences (NASDAQ:ANIX) held its 2026 Annual Meeting of Stockholders via live webcast, outlining the results of shareholder votes and providing an operational update focused on the company’s clinical-stage oncology pipeline and partnership-driven strategy. Annual meeting votes and quorum Pr

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 10, 2026

Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance

Anixa Biosciences (NASDAQ:ANIX) Chairman and CEO Dr. Amit Kumar said the company views 2026 as a “pivotal year” as it advances two clinical-stage programs: a breast cancer vaccine being developed with the Cleveland Clinic and the U.S. Department of Defense, and a CAR-T cell therapy for terminally il

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Feb 8, 2026

Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Nov 13, 2025

Top Penny Stocks To Watch In November 2025

The U.S. stock market has seen a downturn following the end of the longest federal shutdown in history, with major indices slipping as technology shares led declines. Despite these challenges, opportunities remain for investors willing to explore smaller or newer companies often categorized under the term "penny stocks." These stocks can offer significant growth potential at lower price points, especially when they are backed by strong financials and solid fundamentals.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Nov 5, 2025

Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and Boston Scientific (BSX) have performed compared to their sector so far this year.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.